Mannkind (MNKD) Free Cash Flow Growth (1y) (2011 - 2026)
Mannkind (MNKD) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 137.65% |
| 10 | Mannkind | 1.25 Bn | 1.12 Bn | 82.66 Mn | 16.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.03% |
| Dec 31, 2025 | -134.53% |
| Sep 30, 2025 | 162.32% |
| Jun 30, 2025 | 61.94% |
| Mar 31, 2025 | -256.16% |
| Dec 31, 2024 | -0.12% |
| Sep 30, 2024 | 15.15% |
| Jun 30, 2024 | -46.55% |
| Mar 31, 2024 | 160.03% |
| Dec 31, 2023 | 1,102.99% |
| Sep 30, 2023 | 128.09% |
| Jun 30, 2023 | 127.83% |
| Mar 31, 2023 | 61.60% |
| Dec 31, 2022 | 83.35% |
| Sep 30, 2022 | -101.98% |
| Jun 30, 2022 | -44.47% |
| Mar 31, 2022 | -44.93% |
| Dec 31, 2021 | -5,036.26% |
| Sep 30, 2021 | -5.13% |
| Jun 30, 2021 | -487.01% |